Author:
Van Cutsem J,Van Gerven F,Van de Ven M A,Borgers M,Janssen P A
Abstract
Itraconazole is a new orally active triazole derivative with broad-spectrum antifungal activity. This drug is effective in experimental aspergillosis and possesses in vitro activity against various species and strains of Aspergillus. Morphological destruction of inoculated hyphae and complete inhibition of hyphal outgrowth in culture is obtained from 0.07 micrograms ml-1 (10(-7)M) onward. These properties make itraconazole a likely candidate for clinical evaluation in disseminated aspergillosis.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference16 articles.
1. Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use;Aisner J.;Ann. Intern. Med.,1979
2. Borgers M. H. Van den Bossche and M. De Brabander. 1983. The mechanism of action of the new antimycotic ketoconazole. Am. J. Med. 74(Suppl. B):2-8.
3. Borgers M. A.-M. Van de Ven G. Willemsens and H. Van den Bossche. Morphologic evaluation of R 51211 a new antimycotic. 13th International Congress on Chemotherapy Proceedings part 61 SE 4.8/2-13 Vienna Austria 28 August to 2 September 1983.
4. An ultrastructural and cytochemical study of Candida albicans after in vitro treatment with imidazoles;De Nollin S.;Mykosen,1976
5. Graybill J. R. S. R. Kaster and D. J. Drutz. Treatment of murine aspergillosis with BAY N 7133. 13th International Congress on Chemotherapy Proceedings part 20 Sy 49/1-8 Vienna Austria 28 August to 2 September 1983.
Cited by
138 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献